Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports
-- Pfizer has agreed to settle over 10,000 cases against its heartburn drug Zantac for allegedly hiding cancer-associated risks, Bloomberg reports, citing people familiar with the deal.
-- The agreements cover cases in state courts across the U.S., but don't completely resolve the company's exposure to Zantac claims, Bloomberg reports.
-- "Pfizer has explored and will continue to explore opportunistic settlements of certain cases if appropriate, and has settled certain cases," Pfizer said in a statement, according to Bloomberg. "The company has not sold a Zantac product in more than 15 years and did so only for a limited period of time."
-- Zantac has been owned by different drugmakers in its more than 30-year run as one of the most popular antacids in the U.S., Bloomberg reports.
Full article at https://www.bloomberg.com/news/articles/2024-05-08/pfizer-agrees-to-settle-more-than-10-000-zantac-cancer-lawsuits
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 08, 2024 13:47 ET (17:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase